From July 5, the VNVC Vaccination System began implementing the new generation MenACYW brain-ctreated vaccine manufactured by Sanofi Pharmaceutical Company (France) from a factory located in the US nationwide. The vaccine helps prevent the 4 most common serotypes of diseases, A, C, Y, W-135 that cause dangerous diseases such as meningitis and sepsis with more than 135,000 deaths each year worldwide. In particular, it can cause a state of extreme infection that can cause children and adults to die in just a few hours.
After more than 50 years of research and development of generations of vaccine against Bacterial thrombocytopenic purpura, Sanofi has succeeded with breakthrough synthetic technology to create a new generation of vaccine against thrombocytopenic purpura. The new generation MenACYW menACYW vaccine applies a breakthrough technology, using a protein synthesized from the Tet Toxin Solution (TT) with a modern structure of weak and sustainable motor connective linkage, helping to stimulate a strong and sustainable immune response, while reducing the rate of healthy people with pathogens, contributing to cutting the transmission chain in the community.
Unlike the previously approved vaccine that limited the age of vaccination to 55 years old, the MenACYW vaccine is indicated for vaccination of children from 12 months old and adults with no age restrictions, and is expected to be expanded to children from 6 weeks old in the near future. This is the first time in Vietnam that adults aged 56 and over have been vaccinated against scoliosis, which helps protect against dangerous diseases with the highest mortality rate in young children, adolescents and the elderly.
Meningococcal bacteria are usually present in the throat parenchyma, transmitted through the respiratory tract. According to the Ministry of Health, 5-25% of people in the community are "healthy people with parasites", have no symptoms but still spread pathogens, making it difficult to control the epidemic. In crowded environments such as schools, dormitories, military posts, industrial parks, etc., the risk of an outbreak is very high.
Scoliosis often starts silently with symptoms such as fever, headache, sore throat... easily confused with many common diseases, leading to late treatment and ignoring the "golden stage" of treatment. According to statistics, up to 50% of patients with globular encephalitis will die if not detected and treated promptly.
In particular, a thrombocytopenic infection can cause death very quickly, within just 6 to 8 hours if not treated promptly. Among the few survivors, 10-20% have to face serious sequelae such as hearing loss, blindness, limb fracture, neurological disorders, especially newborns with a sequelae rate of up to 50%.
According to data from the UK Public Health Agency, nearly 90% of children and adolescents die from invasive thrombocytopenic purpura within 24 hours of diagnosis.
In Vietnam, in just the first 6 months of 2025, the whole country recorded dozens of cases, including 2 deaths due to brain mobilization. In June 2025, the Pasteur Institute of Ho Chi Minh City warned of the risk of a brain- authoritative outbreak in the southern region.
Statistics at Children's Hospital 1 (HCMC) show that most cases of cerebral and spinal cord disease are admitted to the hospital after 19 hours of spreading the disease, relatively late for medical intervention. Many cases, although saved, had to be amputated, causing patients to be disabled for life, affecting their long-term future.
According to Dr. Bach Thi Chinh, Medical Director, VNVC Vaccination System, in the face of the risk of viruses and bacteria easily spreading in the context of increasingly increasing global economic, social and tourism exchanges, vaccine manufacturers such as Sanofi are researching and developing new-generation brain-spinal vaccine with breakthrough technology to expand the protective spectrum, increase effectiveness, safety and suitability for all ages. This is a great achievement of medical technology, contributing to effectively protecting public health, Dr. Bach Thi Chinh shared.
Speaking at the launching ceremony, Dr. Kuharaj Mahenthiran, Medical Director of Sanofi Vietnam Vaccine, the new generation MenACYW brain-to-spinal vaccine has been approved in more than 70 countries and deployed in nearly 40 countries since 2021. With a broad age range and a solid research foundation, this vaccine will play a key role, a major step forward in protecting Vietnamese people from brain-nhyroid disease.
According to Dr. Chinh, globular vaccine does not have cross-immunity, so people should be vaccinated with all types of vaccines to fully prevent all 5 groups of globular serotypes that cause the disease. Depending on vaccination history, epidemic situation, age and needs, etc., the doctor will prescribe the appropriate vaccine and vaccination schedule to achieve the most optimal protection effect.
Consistent updating of new generation vaccines with high quality, safety and efficiency at the top of the world affirms VNVC's commitment to bringing Vietnamese people to access advanced medical solutions on par with the international level. This is a practical action towards WHO's goal by 2030 to reduce 70% of deaths and 50% of cases of bacterial meningitis, emphasized Dr. Bach Thi Chinh.
